Aswathy R. Devan

458 total citations
18 papers, 303 citations indexed

About

Aswathy R. Devan is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Aswathy R. Devan has authored 18 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Aswathy R. Devan's work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Cancer Mechanisms and Therapy (2 papers). Aswathy R. Devan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Cancer Mechanisms and Therapy (2 papers). Aswathy R. Devan collaborates with scholars based in India, United States and Israel. Aswathy R. Devan's co-authors include Lekshmi R. Nath, Bhagyalakshmi Nair, Vinod Balachandran, K Pavithran, Javad Sharifi‐Rad, Daniela Călina, Hoon Kim, Nikhil Ponnoor Anto, Bijo Mathew and Gautam Sethi and has published in prestigious journals such as International Journal of Pharmaceutics, Drug Discovery Today and World Journal of Gastroenterology.

In The Last Decade

Aswathy R. Devan

17 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aswathy R. Devan India 10 99 83 59 39 34 18 303
Alicja Sznarkowska Poland 10 210 2.1× 115 1.4× 47 0.8× 46 1.2× 22 0.6× 18 433
Sujit Suklabaidya India 11 148 1.5× 105 1.3× 71 1.2× 44 1.1× 14 0.4× 16 359
Swarnendu Bag India 12 123 1.2× 53 0.6× 37 0.6× 29 0.7× 12 0.4× 31 445
Xingyu Rong China 8 245 2.5× 118 1.4× 59 1.0× 50 1.3× 19 0.6× 12 450
Yuqing Wang China 8 146 1.5× 76 0.9× 29 0.5× 35 0.9× 94 2.8× 21 402
Jianyuan Tang China 11 163 1.6× 40 0.5× 74 1.3× 30 0.8× 14 0.4× 24 326
Shenghao Li China 12 166 1.7× 47 0.6× 42 0.7× 57 1.5× 17 0.5× 33 373
Carlemi Calitz Netherlands 13 95 1.0× 55 0.7× 23 0.4× 58 1.5× 34 1.0× 25 336
Bishoy El‐Aarag Egypt 12 133 1.3× 89 1.1× 35 0.6× 29 0.7× 28 0.8× 26 389
Avinash Khadela India 11 101 1.0× 80 1.0× 30 0.5× 32 0.8× 11 0.3× 36 319

Countries citing papers authored by Aswathy R. Devan

Since Specialization
Citations

This map shows the geographic impact of Aswathy R. Devan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aswathy R. Devan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aswathy R. Devan more than expected).

Fields of papers citing papers by Aswathy R. Devan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aswathy R. Devan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aswathy R. Devan. The network helps show where Aswathy R. Devan may publish in the future.

Co-authorship network of co-authors of Aswathy R. Devan

This figure shows the co-authorship network connecting the top 25 collaborators of Aswathy R. Devan. A scholar is included among the top collaborators of Aswathy R. Devan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aswathy R. Devan. Aswathy R. Devan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Devan, Aswathy R., et al.. (2025). Ternary complex of Kaempferol-Hydroxypropyl-β-Cyclodextrin-Liposomes against hepatocellular carcinoma: Preparation, validation, pharmacokinetics and efficacy studies. International Journal of Pharmaceutics. 671. 125261–125261. 3 indexed citations
2.
Devan, Aswathy R., et al.. (2025). Ultrasound imaging-guided protocol for monitoring tumor growth in orthotopic rat model of hepatocellular carcinoma. World Journal of Hepatology. 17(10). 109517–109517.
3.
Devan, Aswathy R., Bhagyalakshmi Nair, Vinod Balachandran, et al.. (2024). The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. European journal of medical research. 29(1). 490–490. 20 indexed citations
4.
Nair, Bhagyalakshmi, et al.. (2024). Unveiling the role of the Hedgehog signaling pathway in chronic liver disease: Therapeutic insights and strategies. Drug Discovery Today. 29(8). 104064–104064. 6 indexed citations
5.
Devan, Aswathy R., et al.. (2023). Kaempferide exhibits an anticancer effect against hepatocellular carcinoma in vitro and in vivo. Naunyn-Schmiedeberg s Archives of Pharmacology. 396(10). 2461–2467. 9 indexed citations
6.
Devan, Aswathy R., Bhagyalakshmi Nair, Kanjoormana Aryan Manu, et al.. (2023). Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence. Cancers. 15(10). 2729–2729. 5 indexed citations
7.
Devan, Aswathy R., Bhagyalakshmi Nair, & Lekshmi R. Nath. (2022). Translational Phytomedicines against Cancer: Promise and Hurdles. Advanced Pharmaceutical Bulletin. 13(2). 210–215. 9 indexed citations
8.
Devan, Aswathy R., et al.. (2022). Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World Journal of Gastroenterology. 28(36). 5250–5264. 22 indexed citations
9.
Nath, Lekshmi R., et al.. (2022). Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma. Current Cancer Drug Targets. 22(9). 725–740. 4 indexed citations
10.
Devan, Aswathy R., et al.. (2021). An insight into the role of telmisartan as PPAR‐γ/α dual activator in the management of nonalcoholic fatty liver disease. Biotechnology and Applied Biochemistry. 69(2). 461–468. 15 indexed citations
11.
Devan, Aswathy R., et al.. (2021). Unravelling the Immune Modulatory Effect of Indian Spices to Impede theTransmission of COVID-19: A Promising Approach. Current Pharmaceutical Biotechnology. 23(2). 201–220. 6 indexed citations
12.
Nair, Bhagyalakshmi, et al.. (2021). Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clinical & Translational Oncology. 24(3). 407–431. 16 indexed citations
13.
Devan, Aswathy R., et al.. (2021). Mucus targeting as a plausible approach to improve lung function in COVID-19 patients. Medical Hypotheses. 156. 110680–110680. 17 indexed citations
14.
Devan, Aswathy R., et al.. (2021). Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Molecular Biology Reports. 48(12). 8075–8095. 83 indexed citations
15.
Devan, Aswathy R., Bhagyalakshmi Nair, Nikhil Ponnoor Anto, et al.. (2021). Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals. 14(7). 656–656. 13 indexed citations
16.
Devan, Aswathy R., et al.. (2021). Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. Journal of Food Biochemistry. 45(7). e13761–e13761. 41 indexed citations
17.
Devan, Aswathy R., et al.. (2021). Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment. Current Drug Targets. 22(11). 1288–1316. 20 indexed citations
18.
Devan, Aswathy R., et al.. (2020). The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. Infectious Disorders - Drug Targets. 21(4). 514–526. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alicja Sznarkowska Breakdown of academic impact, for papers by Sujit Suklabaidya Breakdown of academic impact, for papers by Swarnendu Bag Breakdown of academic impact, for papers by Xingyu Rong Breakdown of academic impact, for papers by Yuqing Wang Breakdown of academic impact, for papers by Jianyuan Tang Breakdown of academic impact, for papers by Shenghao Li Breakdown of academic impact, for papers by Carlemi Calitz Breakdown of academic impact, for papers by Bishoy El‐Aarag Breakdown of academic impact, for papers by Avinash Khadela
Rankless by CCL
2026